ClinicalTrials.gov
ClinicalTrials.gov Menu

To Evaluate Safety and the Pharmacokinetic Characteristics After Oral Administration of HT-003 Compared With Choline Alfoscerate Capsule in Healthy Adult Male Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02395926
Recruitment Status : Completed
First Posted : March 24, 2015
Last Update Posted : March 24, 2015
Sponsor:
Information provided by (Responsible Party):
Hyundai Pharmaceutical Co., LTD.

Brief Summary:

Choline alfoscerate(L-alfa glycerylphosphorylcholine) is a natural compound found in the brain and breast. Choline alfoscerate contains 40.8% of choline and has a produrig structure and separated by a precursor of choline and nerve cell membrane precursor of acetylcholine glycerophosphate. Choline alfoscerate Colin normalization of nerve pathways, nerve cell membrane play and acetylcholine receptor function secondary symptoms caused by cerebrovascular deficiency and indirectly through activation of metabolism, has a degenerative effect on the brain organic mental syndrome.

Currently marketed oral choline alfoscerate received a geriatric cognitive impairment, secondary symptoms and degeneration, or soft capsule is authorized to prescription drugs for degenerative brain organic mental syndrome caused by cerebrovascular deficiency. Gliatilin soft capsules containing 400 mg per 1 capsule 2-3 times one days're supposed to take when considering optimal convenience and efficiency of the drug in patients with the development of sustained release formulations that can be maintained for a long period of time, a certain concentration is required. Accordingly, the modern drug by reducing the frequency of administration a day circuit is to develop a sustained release formulation of choline alfoscerate HT-003 600 mg medication compliance for the purpose of raising. 2 tablets at a time (600 mg x 2) can be taken one day to 1200 mg is required by taking.

Therefore, for the development of sustained release formulation, the test in healthy adult male volunteers targets choline alfoscerate soft capsule formulation of 400mg 3 times per 1 day and sustained-release tablet 600mg 2time per 1 day, pharmacokinetic properties and safety of a single dose should be evaluated when compared.


Condition or disease Intervention/treatment Phase
Healthy Male Drug: Choline CR 600mg Drug: Gliatilin 400mg Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : October 2013
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: R
Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00
Drug: Gliatilin 400mg
Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00

Experimental: T1
HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00
Drug: Choline CR 600mg
HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00

Experimental: T2
HT-003 600mg*2tab, administration 1 times per 1 day 8:00 a.m.
Drug: Choline CR 600mg
HT-003 600mg*2tab, administration 1 times per 1 day 8:00 a.m.




Primary Outcome Measures :
  1. Cmax [ Time Frame: in 24hr after administration ]
  2. AUClast [ Time Frame: in 24hr after administration ]

Secondary Outcome Measures :
  1. baseline-corrected Cmax [ Time Frame: in 24hr after administration and before administration ]
  2. baseline-corrected AUClast [ Time Frame: in 24hr after administration and before administration ]
  3. Tmax [ Time Frame: in 24hr after administration and before administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy male subjects between the ages of 20 and 55 years, inclusive
  2. BMI>=19kg/m2, <=27kg/m2

    *body mass index (kg/m2) = weight (kg)/ [(height (m)2)

  3. Voluntary written consent by the parties that the ability and willingness to participate during the entire period of the test

Exclusion Criteria:

  1. Subjects who has history or clinically significant disease about liver, kidney, digestive, respiratory, musculoskeletal, endocrine, neuropsychiatric, blood•tumor type, cardiovascular disease.
  2. A GFR of less than 60ml/min person, calculated by the MDRD (Modification of Diet in Renal Disease)

    ※ MDRD equation (mL/min/1.73m2) : GFR = 175 x Scr-1.154 x age-0.203

  3. Systolic blood pressure less than 90 mmHg in vital signs is 150 mmHg or diastolic blood pressure less than 50 mmHg or higher or numerical characters shown equal to at least 100 mmHg
  4. Subjects with known for hypersensitivity reaction to components of the investigational drug
  5. Subjects who has history of drug abuse, shows positive in urine drug screening test
  6. Use of any prescription medication within 14 days prior to study medication dosing or use of any medication such as over-the-counter medication including oriental medication within 7 days prior to study medication dosing
  7. Participation in any clinical investigation within 60days prior to study medication dosing
  8. Subjects with whole blood donation within 60days, component blood donation within 30days
  9. Caffeine-containing beverages (coffee, tea, cola) intake or grapefruit / orange juice who exceed the average daily intake of 4 cups.
  10. Subjects who intake average alcohol consumption per week exceeds 140g or cannot be a non-alcohol during the hospital stay.
  11. Subjects who exceed the average daily smoke of 10 cigarettes or cannot be a non-smoking during the hospital stay
  12. Subjects who cannot limit the choline-containing food (liver, cocoa, bean, chocolate, otmil etc), from admitted to the hospital the day before
  13. Subjects who shows positive in serum test (hepatitis B, C, HIV)
  14. Subjects with decision of nonparticipation through investigator's review due to laboratory test results or other excuse such as non-responding to request or instruction by investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02395926


Sponsors and Collaborators
Hyundai Pharmaceutical Co., LTD.
Investigators
Principal Investigator: Jungryul Kim, Ph.D Samsung seoul hospital

Responsible Party: Hyundai Pharmaceutical Co., LTD.
ClinicalTrials.gov Identifier: NCT02395926     History of Changes
Other Study ID Numbers: HT-003-01
First Posted: March 24, 2015    Key Record Dates
Last Update Posted: March 24, 2015
Last Verified: February 2015

Additional relevant MeSH terms:
Choline
Lipotropic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents
Lipid Regulating Agents
Nootropic Agents